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might be involved in high affinity transport of endoge- At the canalicular plasma membrane monoquaternary
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nine) are transported in a stereospecific manner by ratrole in overall amphipathic drug clearance by the liver
Mdr1b and human MDR1, but not by Mdr2 [12].and other drug eliminating organs. Since the Oatps/
OATPs can remove amphipathic drugs from their albu-
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at the level of intestine, liver and kidney. On the otherThe last session was opened by Martin Fromm (Stutt-
hand, the antibiotic rifampicin enhances P-glycoproteingart, Germany), who talked about “ABC transporters and
(P-gp) expression and causes reduced plasma concentra-drug disposition.” Clinically important are, for example,
tions of P-gp substrates. In addition, a widespread C3435Tdrug-drug interactions such as the enhancement of blood
mutation of P-gp has been shown to be associated withconcentrations of the heart glycoside digoxin during con-
low level P-gp expression in gut and higher bioavailabilitycomitant treatment with the anti-arrhythmic drug quinidine
of digoxin in Caucasians [2].[1]. The underlying mechanism is inhibition of P-glycopro-
tein mediated digoxin transport, which occurs most likely Alfred Schinkel (Amsterdam, The Netherlands)
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stressed the importance of “In vivo P-gp inhibition to cholic acid modestly up-regulates via PXR Mrp2; in addi-
tion Mrp 4 is strongly up-regulated via PXR and theimprove the pharmacological behavior of HIV-protease
phenobarbital-sensitive nuclear factor CAR as well. Sinceinhibitors” such as of saquinavir and ritonavir. He showed
Mrp4 is present in the basolateral membrane of hepato-that combined application of ritonavir with saquinavir
cytes as well as in cholangiocytes, this ABC-carrier estab-increased blood levels of saquinavir by retarding its elim-
lishes a detoxification pathway under high bile salt load-ination, probably primarily by inhibition of its metabo-
ing, for example, during cholestasis [4].lism by the P450 protein Cyp 3A4. If an inhibitor of P-
gp was given in addition, blood and brain levels increased
REFERENCESeven further [3]. Improvements of saquinavir pharmaco-
kinetics are particularly important for fetuses from HIV- 1. Fromm MF, Kim RB, Stein CM, et al: Inhibition of P-glycoprotein-
mediated drug transport: A unifying mechanism to explain the inter-infected woman, since protective drug preloading of the
action between digoxin and quinidine. Circulation 99:552–557, 1999fetuses is feasible. 2. Hoffmeyer S, Burk O, von Richter O, et al: Functional polymor-
In his lecture, John Schuetz (Memphis, Tennessee, phisms of the human multidrug-resistance gene: Multiple sequence
variations and correlation of one allele with P-glycoprotein expres-USA) presented results about the “Interactions between
sion and activity in vivo. Proc Natl Acad Sci USA 97:3473–3478,nuclear receptors, ABC transporters, and cytochromes 2000
3. Huisman MT, Smit JW, Wiltshire HR, et al: P-glycoprotein limitsP450.” He used knockout mice with deficiency in nuclear
oral availability, brain, and fetal penetration of saquinavir even withtranscription factor FXR (farnesoid-X-receptor) to show
high doses of ritonavir. Mol Pharmacol 59:806–813, 2001
that the expression of the mouse bile acid export pump 4. Schuetz EG, Strom S, Yasuda K, et al: Disrupted bile acid homeo-
stasis reveals an unexpected interaction among nuclear hormone(Bsep) by bile acids is detoriated. Such mice have in-
receptors, transporters, and cytochrome P450. J Biol Chem 276:creased bile acid levels in blood and overexpressed
39411–39418, 2001
CYP3A11, CYP2B10 and Mrp4. This points to an impor-
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